Dr Alison Foster BSc, MBBS, MRCPCH

Institute of Cancer and Genomic Sciences
Academic Clinical Research Fellow
Registrar Clinical Genetics

Contact details

Institute of Cancer and Genomic Sciences
University of Birmingham
B15 2TT

Alison Foster is a Research Fellow in the Institute of Cancer and Genomics and a Registrar in Clinical Genetics at Birmingham Women’s Hospital. Her PhD is investigating the clinical and molecular features of rare genetic overgrowth disorders under the supervision of Professor Tim Barrett and Dr Trevor Cole.


  • RCP Certificate in Medical Genetics, 2015
  • MRCPCH, 2011
  • MBBS Honours (with Distinction), University of Newcastle upon Tyne, 2007
  • BSc 1st Class (Hons) Human Genetics, University College London, 2003


Alison Foster received her BSc in Human Genetics from UCL in 2003 and went on to study graduate entry medicine at the University of Newcastle upon Tyne. Following graduation from medical school in 2007, she completed Foundation training in the Newcastle upon Tyne Hospitals before moving to the West Midlands to train in Paediatrics. In 2012 she commenced training in Clinical Genetics and in 2014 was awarded a Doctoral Fellowship by the NIHR Rare Diseases Translational Research Collaboration (RD-TRC). She is undertaking her PhD in the Institute of Cancer and Genomics and is Chief Investigator for the Phenotyping of Overgrowth (POD) study.



Her research is focused on establishing the phenotypic spectrum and genotype-phenotype correlations in known and emerging rare genetic overgrowth disorders.


Brioude F, Kalish JM, Mussa A, Foster AC, Bliek J, Ferrero GB, Boonen SE, Cole T, Baker R, Bertoletti M, Cocchi G, Coze C, De Pelegrin M, Hussain K, Ibrahim A, Kilby MD, Krajewska-Walasek M, Kratz CP, Ladusans EJ, Lapunzina P, Le Bouc Y, Maas SM, MacDonald F, Ounap K, Peruzzi L, Rossignol S, Russo S, Shipster C, Skorka A, Tatton-Brown K, Tenorio J, Tortora C, Gronskiv K, Nethcine I, Hennekam RC, Prawitt D, Tumer,Z, Eggerman T, Mackay DJG, Riccio A, Maher ER. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol. 2018 14(4):229-249. 

Griffiths S, Loveday C, Zachariou A, Behan L, Chandler K, Cole T, D’Arrigo S, Dieckmann A, Foster A, Gibney J, Hunter M, MIlani D, Pantaleoni C, Roche E, Sherlock M, Springer A, White, SM, Childhood Overgrowth Collaboration, Tatton-Brown K. EED and EZH2 constitutive variants: A study to expand the Cohen-Gibson syndrome phenotype and contrast it with Weaver syndrome. Am J Hum Genet 2019; 179A:588-594  

Cleaver R, Berg, J, Craft E, Foster A, Gibbons RJ, Hobson E, Lachlan K, Naik S, Sampson JR, Sharif S, Smithson S, Decipehring Developmental Disorders Study, Parker MJ, Tatton-Brown K. Refining the Primrose syndrome phenotype: A study of five patients with ZBTB20 de novo variants and a review of the literature. Am J Med Genet A 2018; 1-6 

Priolo M, Schanze D, Tatton-Brown K, Mulder PA, Tenoria J., Kooblall K, Hernandez Acero I. Alkuraya FS, Arias P, Bernardini L, Bijlsma EK, Cole T, Coubes C, Dapia I, Davies S, Di Donato N, Elcioglu NH, Fahrner JA, Foster A, Garcia Gonzalez NH, Huber I, Iascone M, Kaiser A, Kamath A, Liebelt J, Lynch S, Maas S, Mammi C, McKee S, Menke LA, Mirzaa GM, Tontgomery T, Neubauer D, Neumann TE, Pintomall L, Pisanti MA, Plomp AS, Price S, Salter C, Santos-Simarro F, Sarda P, Segovia M, Shaw-Smith C, Smithson S, Suri M, Valdez RM, Van Haeringen A, Van Hagen JM, Zollino M, Lapunzina P, Thakker, RV, Zenker M, Hennekam RC. Further delineation of Malan syndrome. Human Mutation 2018 13:1226-1237

Menke LA, van Belzen MJ, Alders M, Cristofoli F; DDD Study., Ehmke N, Fergelot P, Foster A, Gerkes EH, Hoffer MJ, Horn D, Kant SG, Lacombe D, Leon E, Maas SM, Melis D, Muto V, Park SM, Peeters H, Peters DJ, Pfundt R, van Ravenswaaij-Arts CM, Tartaglia M, Hennekam RC. CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype. Am J Med Genet A. 2016. Oct;170(10):2681-93.

Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J, Suvisaari J, Chheda H, Blackwood D, Breen G, Pietiläinen O, Gerety SS, Ayub M, Blyth M, Cole T, Collier D, Coomber EL, Craddock N, Daly MJ, Danesh J, DiForti M, Foster A, Freimer NB, Geschwind D, Johnstone M, Joss S, Kirov G, Körkkö J, Kuismin O, Holmans P, Hultman CM, Iyegbe C, Lönnqvist J, Männikkö M, McCarroll SA, McGuffin P, McIntosh AM, McQuillin A, Moilanen JS, Moore C, Murray RM, Newbury-Ecob R, Ouwehand W, Paunio T, Prigmore E, Rees E, Roberts D, Sambrook J, Sklar P, St Clair D, Veijola J, Walters JT, Williams H; Swedish Schizophrenia Study.; INTERVAL Study.; DDD Study.; UK10 K Consortium., Sullivan PF, Hurles ME, O'Donovan MC, Palotie A, Owen MJ, Barrett JC. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci. 2016 Apr;19(4):571-7

Foster A, Titheradge H, Morton J. Genetics of Learning Disability. Paediatrics and Child Health. 2015. Vol. 25, Issue 10, p450-457.

Tummala H, Walne A, Collopy L,Cardoso S, de la Fuente J, Lawson S, Powell J, Cooper N, Foster A, Mohammed S, Plagnol V, Vulliamy T, Dokal, K. Poly(A)-specific ribonuclease deficiency impacts on telomere biology causing dyskeratosis congenita. The Journal of Clinical Investigation. 2015. 125(5):2151-2160.

View all publications in research portal